BSE Live
Prev. Close
Open Price
Bid Price (Qty.)
()
Offer Price (Qty.)
()
NSE Live
Nov 07, 15:48Prev. Close
42.26
Open Price
42.09
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Balaxi Pharmaceuticals (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | |
| 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | |||||
| Revenue From Operations [Gross] | 0.12 | 0.14 | 0.07 | 0.06 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 0.12 | 0.14 | 0.07 | 0.06 | |
| Total Operating Revenues | 0.12 | 0.14 | 0.07 | 0.06 | |
| Other Income | 0.12 | 0.05 | 0.02 | 0.13 | |
| Total Revenue | 0.24 | 0.19 | 0.09 | 0.19 | |
| EXPENSES | |||||
| Cost Of Materials Consumed | 0.00 | 0.00 | 0.00 | 0.00 | |
| Purchase Of Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | |
| Employee Benefit Expenses | 0.02 | 0.01 | 0.01 | 0.01 | |
| Finance Costs | 0.01 | 0.01 | 0.00 | 0.00 | |
| Depreciation And Amortisation Expenses | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Expenses | 0.05 | 0.02 | 0.02 | 0.04 | |
| Total Expenses | 0.09 | 0.04 | 0.03 | 0.05 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 0.15 | 0.15 | 0.06 | 0.14 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 0.15 | 0.15 | 0.06 | 0.14 | |
| Tax Expenses-Continued Operations | |||||
| Current Tax | 0.04 | 0.04 | 0.01 | 0.02 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 0.04 | 0.04 | 0.01 | 0.02 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 0.10 | 0.11 | 0.04 | 0.12 | |
| Profit/Loss From Continuing Operations | 0.10 | 0.11 | 0.04 | 0.12 | |
| Profit/Loss For The Period | 0.10 | 0.11 | 0.04 | 0.12 | |
| OTHER ADDITIONAL INFORMATION | |||||
| EARNINGS PER SHARE | |||||
| Basic EPS (Rs.) | 0.50 | 1.56 | 0.63 | 1.70 | |
| Diluted EPS (Rs.) | 0.50 | 1.56 | 0.63 | 1.70 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | |||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | |||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | |||||
| Equity Share Dividend | 0.09 | 0.07 | 0.06 | 0.07 | |
| Tax On Dividend | 0.02 | 0.01 | 0.01 | 0.01 | |
| Equity Dividend Rate (%) | 3.00 | 10.00 | 9.00 | 10.00 |
12.08.2025
Balaxi Pharma Consolidated June 2025 Net Sales at Rs 70.74 crore, up 7.8% Y-o-Y
06.08.2025
Balaxi Pharma Standalone June 2025 Net Sales at Rs 16.71 crore, down 12.18% Y-o-Y
24.06.2025
Balaxi Pharma Standalone March 2025 Net Sales at Rs 9.65 crore, down 39.33% Y-o-Y
20.02.2025
Balaxi Pharma Consolidated December 2024 Net Sales at Rs 73.29 crore, up 20.57% Y-o-Y
12.08.2025
Balaxi Pharma Consolidated June 2025 Net Sales at Rs 70.74 crore, up 7.8% Y-o-Y
06.08.2025
Balaxi Pharma Standalone June 2025 Net Sales at Rs 16.71 crore, down 12.18% Y-o-Y
24.06.2025
Balaxi Pharma Standalone March 2025 Net Sales at Rs 9.65 crore, down 39.33% Y-o-Y
20.02.2025
Balaxi Pharma Consolidated December 2024 Net Sales at Rs 73.29 crore, up 20.57% Y-o-Y
15.06.2017
24.04.2017
18.04.2017
18.04.2017
14.02.2017
13.02.2017
12.02.2017
09.12.2016